Gilead Sciences (GILD) Other Non-Current Assets (2009 - 2026)

Gilead Sciences (GILD) posted Other Non-Current Assets of $4.6 billion for Q1 2026, down 6.01% quarter-over-quarter from $4.8 billion in Q4 2025, and up 17.64% year-on-year from $3.9 billion in Q1 2025.

Gilead Sciences (GILD) Other Non-Current Assets (2009 - 2026) Analysis & Trends

Gilead Sciences (GILD) has reported Other Non-Current Assets for 18 consecutive years, with $4.6 billion the latest figure, recorded in Q1 2026.

  • Other Non-Current Assets for Q1 2026 came in at $4.6 billion, up 17.64% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.6 billion (up 17.64% YoY), and the FY2025 annual result was $4.8 billion, up 28.55% from the prior year.
  • Other Non-Current Assets was $4.6 billion for Q1 2026 at Gilead Sciences, down from $4.8 billion in the prior quarter.
  • Over five years, Other Non-Current Assets peaked at $5.5 billion in Q3 2024 and troughed at $3.8 billion in Q4 2024.
  • Average Other Non-Current Assets over 5 years is $4.7 billion, with a median of $4.8 billion recorded in 2022.
  • Year-over-year, Other Non-Current Assets jumped 30.81% in 2024 and decreased 25.39% in 2025.
  • Over 5 years, Other Non-Current Assets stood at $4.8 billion in 2022, then retreated by 0.17% to $4.8 billion in 2023, then retreated by 21.35% to $3.8 billion in 2024, then rose by 28.55% to $4.8 billion in 2025, then decreased by 6.01% to $4.6 billion in 2026.
  • Per Business Quant data, the three most recent Other Non-Current Assets figures were $4.6 billion in Q1 2026, $4.8 billion in Q4 2025, and $4.9 billion in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Other Non-Current Assets (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn 7.23 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn 14.11 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn 10.54 Bn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn -
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn 19.81 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn 12.76 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn 4.55 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn 9.83 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn - 200.00 Mn
10 Biogen 30.87 Bn 26.59 Bn 1.82 Bn 777.50 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 4.55 Bn
Dec 31, 2025 4.85 Bn
Sep 30, 2025 4.87 Bn
Jun 30, 2025 4.03 Bn
Mar 31, 2025 3.87 Bn
Dec 31, 2024 3.77 Bn
Sep 30, 2024 5.49 Bn
Jun 30, 2024 4.77 Bn
Mar 31, 2024 5.19 Bn
Dec 31, 2023 4.79 Bn
Sep 30, 2023 4.20 Bn
Jun 30, 2023 5.11 Bn
Mar 31, 2023 4.95 Bn
Dec 31, 2022 4.80 Bn
Sep 30, 2022 4.62 Bn
Jun 30, 2022 4.86 Bn
Mar 31, 2022 5.13 Bn
Dec 31, 2021 4.96 Bn
Sep 30, 2021 4.74 Bn
Jun 30, 2021 5.55 Bn